Clinical Report: Feasibility and Long-Term Outcomes of Target-Prioritized IMRT

Overview

This study evaluates the feasibility and safety of a target-prioritized intensity-modulated radiotherapy (IMRT) strategy for locally advanced nasopharyngeal carcinoma (NPC) near the spinal cord. Results indicate no clinically diagnosed radiation myelopathy in the overall cohort.

Background

Nasopharyngeal carcinoma (NPC) is a significant health concern, particularly in advanced stages where tumors may be close to critical structures like the cervical spinal cord. Traditional spinal cord dose constraints can limit effective target coverage in these cases, necessitating alternative strategies. The target-prioritized IMRT approach aims to balance adequate tumor coverage while minimizing the risk of radiation-induced myelopathy.

Data Highlights

Key Findings

• No clinically diagnosed radiation myelopathy was observed in the overall cohort (upper one-sided 95% CI, 0.33%).
• The 5-year local relapse-free survival (LRFS) was 92.8% and overall survival (OS) was 86.8% for the entire cohort.
• In the target-prioritized cohort, the median spinal cord Dmax was 56.2 Gy, with 20.8% of patients exceeding 60 Gy.
• The cumulative burden score was significantly associated with target-prioritized planning (trend OR, 1.906; P = 0.001).
• In the target-prioritized cohort, the 5-year LRFS and OS rates were 87.9% and 74.2%, respectively.

Clinical Implications

Clinicians should consider the findings of this study when evaluating treatment options for NPC patients with tumors near the spinal cord.

Conclusion

The target-prioritized IMRT strategy was evaluated in selected cases of NPC, with results indicating no clinically diagnosed radiation myelopathy.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Target-Prioritized IMRT for Nasopharyngeal Carcinoma
2. Journal of Neuro-Oncology — Combining Intraoperative Radiotherapy with Spinal Stabilization Surgery: A New Approach for Treating Spinal Metastases Based on Initial Single-Center Findings
3. Frontiers in Oncology — Comparative study of three treatment approaches on overall survival and treatment response in nasopharyngeal carcinoma patients: network meta-analysis of RCTs (4221 patients)
4. The ASCO Post — Proton Therapy Associated With Fewer Sequelae in the Treatment of Head and Neck Cancer
5. asco ai in oncology — Interpretable AI for Stratifying Risk for Immunoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
7. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
8. Microsoft Word - 0615 Master 2-16-11.doc
9. Nasopharyngeal Carcinoma Treatment (PDQ®) - NCI
10. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas - ScienceDirect
11. Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis - ScienceDirect
12. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma - PMC
13. Radiation Dose-volume Effects in the Spinal Cord
14. Dose-Volume Histogram Compendium of Dose Constraints for Treatment Planning: An ASTRO Consensus Paper - ScienceDirect
15. Frontiers | Target-Prioritized IMRT for Nasopharyngeal Carcinoma with Tumour Proximity to the Spinal Cord: Clinical Feasibility and Long-Term Outcomes